BHVN:NYE-Biohaven Pharmaceutical Holding Company Ltd (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 84.03

Change

0.00 (0.00)%

Market Cap

USD 5.20B

Volume

0.91M

Average Target Price

USD 101.46 (+20.74%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut. Address: 215 Church Street, New Haven, CT, United States, 06510

Company Website : http://www.biohavenpharma.com

Address : 215 Church Street, New Haven, CT, United States, 06510

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.08

52 Week High : 100.77

Short Ratio : 8.14

52 Week Low : 26.56

Shorted Shares : 5,298,067

200 Day Moving Average : 79.46

Shorted Shares Previous Month : 5,083,322

50 Day Moving Average : 83.59

Shares Held By Insiders : 137.9%

Short Percentage : 9.00%

Shares Held by Institutions : 117.55%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

N/A

 USD163.53B 28.27 2.82
ADPT Adaptive Biotechnologies Corpo..

N/A

 USD5.88B 43.96 N/A
RCUS Arcus Biosciences, Inc

N/A

 USD2.37B N/A N/A
MYOV Myovant Sciences Ltd

N/A

 USD1.99B N/A N/A
ADCT ADC Therapeutics SA

N/A

 USD1.75B -99,999.99 N/A
ZYME Zymeworks Inc

N/A

 USD1.52B 300.20 N/A
CVM CEL-SCI Corporation

N/A

 USD0.79B N/A N/A
RFL Rafael Holdings, Inc

N/A

 USD0.51B N/A N/A
PFNX Pfenex Inc

N/A

 USD0.44B 268.67 63.90
IBIO iBio, Inc

N/A

 USD0.31B N/A N/A

ETFs Containing BHVN

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.96% 25% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.96% 25% F 24% F
Trailing 12 Months  
Capital Gain 81.84% 72% C- 89% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.84% 72% C- 88% B+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 30.11% 72% C- 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.11% 72% C- 94% A
Risk Return Profile  
Volatility (Standard Deviation) 35.77% 48% F 16% F
Risk Adjusted Return 84.19% 96% A 86% B
Market Capitalization 5.20B 93% A 75% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 31.82 12% F 2% F
Price / Cash Flow Ratio -7.40 43% F 89% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1,116.69% 7% F 0% N/A
Return on Assets -78.23% 19% F 0% N/A
Debt to Equity Ratio -68.51% 67% D+ 96% A
Technical Ratios  
Short Ratio 8.14 11% F 5% F
Short Percent 12.00% 12% F 30% F
Beta 1.08 64% D 50% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector